RT Journal Article
SR Electronic
T1 Steroid-responsive severe encephalopathy in SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.12.20062646
DO 10.1101/2020.04.12.20062646
A1 Pilotto, Andrea
A1 Odolini, Silvia
A1 Masciocchi, S Stefano
A1 Comelli, Agnese
A1 Volonghi, Irene
A1 Gazzina, Stefano
A1 Nocivelli, Sara
A1 Pezzini, Alessandro
A1 Focà, Emanuele
A1 Caruso, Arnaldo
A1 Leonardi, Matilde
A1 Pasolini, Maria Pia
A1 Gasparotti, R Roberto
A1 Castelli, F Francesco
A1 Padovani, Alessandro
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.12.20062646.abstract
AB SARS-CoV-2 infection has the potential for targeting central nervous system and several neurological symptoms have been described in patients with severe respiratory distress. Here we described the case of an otherwise healthy 60-year old subject with SARS-CoV-2 infection but only mild respiratory abnormalities who developed severe progressive encephalopathy associated with mild pleocytosis and hyperproteinorrachia. MRI was negative whereas EEG showed theta waves on the anterior brain regions. Serum and CSF analyses excluded other known infectious or autoimmune disorders. The patient dramatically improved after high-doses steroid treatment suggesting an inflammatory-mediated brain involvement related to SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was not financially supported.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon responsible request by contacting the corresponding author